PPH Prevention

When given within three hours of birth, tranexamic acid (TXA) reduces deaths due to bleeding in women with postpartum haemorrhage (PPH). However, for many women, the treatment of PPH is too late to prevent death. Over one-third of pregnant women in the world are anaemic and many are severely anaemic.

 

These women have an increased risk of PPH and suffer more severe outcomes if PPH occurs. There is an urgent need to identify a safe and effective way to reduce postpartum bleeding in anaemic women. 

 

 

The WOMAN-2 trial investigates if we can use TXA to prevent PPH from happening in the first place 

Current Research

TXA for PPHThe WOMAN-2 Trial

The WOMAN-2 trial is an international, randomised, double-blind, and placebo-controlled trial that investigates giving tranexamic acid to prevent PPH and other severe outcomes in women with moderate and severe anaemia. 

More Resources

Click on watch, read or teach to access videos, publications, and training materials 

WOMAN-2: Trial Procedure

How patients are collected and assessed during the trial

 

WOMAN-2: Study Protocol

View PDF

 

WOMAN-2: Finding Better Ways to Prevent Postpartum Hemorrhage

View PDF

 

WOMAN-2: Background, Rationale & Overview

View PDF

More Treatments

TXAcentral is a resource for health professionals caring for people with acute bleeding
TXAcentral brings together randomised trial evidence on the effectiveness and safety of tranexamic acid
Data on many of the trials are also available at the freeBIRD website

In trauma patients with significant bleeding and those with traumatic brain injury (TBI), TXA has been  shown to reduce mortality in both extracranial and intracranial bleeding

Postpartum Haemorrhage (PPH) is the leading cause of maternal death worldwide, responsible for around 100 000 deaths each year. TXA given as quickly as possible after birth and no later than 3 hours, reduces death due to bleeding and the need for surgery to stop bleeding

GI Bleeding is a common emergency that causes substantial mortality and morbidity worldwide. TXA was found to not reduce deaths from GI bleeding and showed an increased risk of thromboembolic events

Every year there are over 300 million surgical procedures worldwide. Bleeding is an important complication and many patients require a blood transfusion. TXA reduces blood loss in surgical patients by about one‐third. However, the effects of TXA on thromboembolic events and mortality in surgery are uncertain

There is ongoing research looking at how Tranexamic Acid (TXA) could be utilised for other bleeding conditions